Navigation Links
Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients

Maxygen, Inc. today announced that it has initiated a phase IIa trial to evaluate the efficacy, safety and tolerability of MAXY-G34 in the treatment of chemotherapy-induced neutropenia . MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) shown in preclinical and Phase I studies to have novel and potentially superior properties compared to the current PEG- GCSF therapy.

"Patients and physicians have limited options for treatment of neutropenia," said Russell Howard, chief executive officer of Maxygen. "With MAXY-G34, we hope to expand those options and improve the outcome for many chemotherapy patients. During this first Phase II trial we will begin to learn more about how our drug might play a role in the large, undifferentiated GCSF market."

The Phase IIa trial, which will be conducted at multiple centers in Eastern Europe, is the first trial of MAXY-G34 in patients. Approximately 30 patients with Stage I-III breast cancer will undergo TAC (docetaxel, adriamycin and cyclophosphamide) chemotherapy followed by next-day administration of either MAXY-G34 or Neulasta (control population). The trial is designed as a multiple ascending dose study, with planned doses at 10, 30, 60, or 100 micrograms per kilogram of MAXY-G34 compared to 6mg of Neulasta. Both MAXY-G34 and Neulasta will be administered as a single subcutaneous injection once per chemotherapy cycle.

The primary objective of the Phase IIa trial is to identify one or more doses of MAXY-G34 that effectively treat chemotherapy-induced neutropenia. Patient tolerability, safety, and immunogenicity will be monitored and assessed. Data will also be collected on the pharmacokinetic properties of MAXY-G34 and the mobilization of CD34+ stem cells.

Phase I Results

A Phase I trial was previously conducted to assess the safety and tolerability of MAXY-G34 in 40 healthy volunteers. This study showed MAXY-G34 to be a potent , long-lasting stimulator of neutrophils and an efficient mobilizer of CD34+ stem cells. The drug exhibited a median half-life approximately 2.3 times that of Neulasta. No serious adverse events were reported, and there were no dose-limiting toxicities. No binding or neutralizing antibodies were found at any dose level, with dose levels ranging from 10 - 150 micrograms per kilogram.


'"/>




Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
6. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
7. SARS-Free Taiwan to Mark End Phase of Global Fight
8. Spray on contraceptive clears Phase I trial
9. Phase 3 trials of two multi-kinase inhibitors against cancer
10. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
11. Phase II trails of new HIV vaccine to be held in South Africa
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2017)... ... 24, 2017 , ... Dr. Curry Leavitt, a noted periodontist ... Practice) continuing education (CE) series. As a compassionate and dedicated clinician, Dr. Curry ... numerous CE courses each year. His recent course, Course II of HP3, focused ...
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career ... about Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The ... time, will be presented by Captain Rommie Duckworth, LP, a career fire captain as ...
(Date:5/24/2017)... ... May 24, 2017 , ... If you are thinking of a visit to San ... architecture, October is the perfect time to visit. , Business Architecture Associates is pleased to ... offering for individuals, as a 4-½ day package for individuals, and as 4-½ day corporate ...
(Date:5/24/2017)... ... 24, 2017 , ... Rob Lowe is a sought after actor, and also ... brings the public important topics from all aspects of life, and a new segment ... surrounding feet and ankles. , Podiatry is essential to people’s overall well-being, and if ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., ... for the food and beverage industry offers Citri-Fi®, a natural citrus fiber, to ... purchasing decision process. As a result, labels need to deliver simple, transparent and ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/4/2017)... May 4, 2017  A recent study published ... Ultraviolet-C light as a means of disinfection ... to reduce bioburden on anesthesia workstations. In the ... high-touch, complex medical equipment surfaces contaminated with three ... "This study further validates the body of ...
Breaking Medicine Technology: